- Report
- January 2023
- 145 Pages
Europe
From €3160EUR$3,450USD£2,686GBP
- Report
- December 2024
- 80 Pages
India
From €3206EUR$3,500USD£2,725GBP
- Report
- April 2024
- 185 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- April 2024
- 185 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- April 2024
- 180 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- April 2024
- 183 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- August 2022
- 110 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- January 2024
- 200 Pages
Global
From €3802EUR$4,150USD£3,231GBP
- Report
- March 2024
- 300 Pages
Global
€4576EUR$4,995USD£3,889GBP
- Report
- December 2023
- 158 Pages
Global
€4576EUR$4,995USD£3,889GBP
- Report
- April 2022
- 56 Pages
Global
From €3527EUR$3,850USD£2,997GBP
- Report
- March 2025
- 89 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- July 2023
- 78 Pages
Global
From €3500EUR$4,093USD£3,079GBP

The Self Administration market within the Medical Devices industry is a rapidly growing sector, focusing on the development of products that allow patients to self-administer treatments and medications. This includes devices such as auto-injectors, inhalers, and digital health solutions. These products are designed to provide patients with greater autonomy and convenience, while also reducing the burden on healthcare providers.
The Self Administration market is driven by a number of factors, including the increasing prevalence of chronic diseases, the need for improved patient outcomes, and the growing demand for cost-effective treatments. Additionally, the emergence of new technologies, such as connected devices and artificial intelligence, is expected to further drive the growth of this market.
Some of the major companies in the Self Administration market include Becton Dickinson, Novo Nordisk, Sanofi, Mylan, and Teva Pharmaceuticals. Other notable players include Amgen, Eli Lilly, Merck, Pfizer, and Roche. Show Less Read more